Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) announced today the nomination of Dr. Wolfgang Hofmann for election as an independent member of the Supervisory Board at the company's upcoming Annual General Meeting (AGM) on June 11, 2026. The AGM agenda also includes the previously announced nomination of Dieter Weinand as Chairman of the Supervisory Board and a proposal to increase the board size from six to seven members.
Following constructive discussions, Evotec has entered into a cooperation agreement with MAK Capital Fund LP, a key shareholder. Under the terms, MAK Capital agreed to customary voting and cooperation commitments.
Prof. Dr. Iris Low-Friedrich, Chairwoman of Evotec's Supervisory Board, stated: "We are pleased to nominate Wolfgang for election at the upcoming AGM. His appointment would contribute oversight and governance capabilities through additional industry, scientific and governance expertise, complementing our existing Board structure as we continue to implement our transformation plans to grow shareholder value. The agreement reached reflects Evotec's commitment to constructive shareholder engagement, supporting the long-term success of the Company."
Michael A. Kaufman, CEO of MAK Capital, commented: "We appreciate the constructive dialogue and welcome Wolfgang's nomination to the Supervisory Board. We look forward to continuing our collaboration with the Supervisory Board and Management Board to support Evotec's ongoing transformation."
Evotec is a life science company pioneering drug discovery and development by integrating breakthrough science with AI-driven innovation. The company's expertise spans small molecules, biologics, cell therapies, and associated modalities, supported by proprietary platforms. Evotec works with all Top 20 Pharma companies, over 800 biotechs, and academic institutions. With a portfolio of over 100 proprietary R&D assets, most co-owned, the company focuses on oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec's global team of over 4,500 experts operates from sites in Europe and the U.S. More information is available at www.evotec.com.
This development is significant as it signals Evotec's commitment to strengthening corporate governance and aligning with shareholder interests during its transformation. The nomination of Dr. Hofmann, an independent candidate, is expected to enhance oversight capabilities. The cooperation agreement with MAK Capital indicates a constructive dialogue between the company and its investors, which could foster stability and support long-term value creation. The expansion of the Supervisory Board to seven members reflects a move toward more robust governance structures, potentially impacting Evotec's strategic direction and operational focus.
